LatchBio
LatchBio builds AI agents for biology on a platform of data, registry, workflow, and compute tools for biotech R&D.
Founded
2021LatchBio builds AI agents for biology on a platform of data, registry, workflow, and compute tools for biotech R&D.
LatchBio describes itself as the most well-funded company in its category, citing roughly $33 million raised from investors including Coatue, Lux Capital, Laura Deming, and George Church. Its validated cloud environment emphasizes security and compliance controls, including HIPAA, GxP, and SOC 2 Type II attestations, which it markets toward regulated biopharmaceutical enterprises.
Customer testimonials on the company's site report large analysis-time reductions, including a genomics provider that moved multi-week customer analyses to about a day and a biotechnology firm that reported an eighty percent reduction in RNA-sequence analysis costs. The company also white-labels analysis portals for kit and assay providers at no per-customer charge.
Source: latch.bio
LatchBio's leadership argues that biology will adopt autonomous AI gradually, accelerating first where work is executable, feedback-rich, and economically constrained, such as data analysis. The company's chief technology officer has written that molecular data generation is following an exponential curve while analysis costs are rising faster than reagent and preparation labor.
From this trajectory the company concludes that the bottleneck in life-sciences research will shift from producing measurements to interpreting them, as future datasets outgrow human analytical capacity. This outlook underpins LatchBio's focus on agentic analysis tooling rather than fully autonomous experimentation.
Source: blog.latch.bio
Latch Biosecurity, the company's biosecurity unit formed through the TwentyTwo acquisition, helps frontier AI laboratories evaluate and audit their systems for biological risk. Its offerings include continuously updated benchmarks, independent pre-deployment audits intended to feed responsible scaling policies, red-teaming, and agentic know-your-customer screening.
The unit cites a fastest-analysis prize in DARPA's Bio-Attribution Challenge and research on machine-learning methods that predict viral evolution as background for its evaluation work. It positions biosecurity evaluation as core infrastructure that must improve alongside AI capabilities in biology.
Source: latch.bio
LatchBio offers a modern data and compute agent for biotech R&D alongside a bundled platform spanning Latch Data, Latch Registry, Latch Workflow Manager, and Latch Pods. Latch Data provides compliant cloud storage with imports from common biotech tools, Latch Registry harmonizes experimental metadata in spreadsheet-like tables with a Python API, the Workflow Manager orchestrates Nextflow-native analyses, and Latch Pods supply on-demand cloud computers for interactive work.
The company positions the platform for biotech and pharma research teams as well as diagnostics and kit providers, with validated environments that support HIPAA and SOC 2 Type II requirements. Customers can move data in from services such as Benchling, AWS, Google Cloud, and Azure and scale compute from notebook jobs to multi-GPU workloads.
Source: latch.bio